Robert Blum
CEO Blum aspires to transform Cytokinetics into the next Gilead or Genentech, leveraging his 20+ years of leadership and successful drug foundations like MyoKardia.
Despite not launching a drug in 20 years, Blum's passion and fundraising prowess have kept Cytokinetics afloat, culminating in positive Phase 3 results for afikomten.
Former colleagues praise Blum's leadership and financial acumen but note his tendency to set aggressive goals and micromanage.
By submitting this form, you are agreeing to ManagementTrack’s Privacy Policy. You can choose to opt out of marketing or advertising emails using the ‘unsubscibe’ link included in our emails.
The best
The best
The best
Our investigative journalists interview the top former colleagues of the CEOs you care about.
Our former buysider analysts summarize the key strengths & weaknesses, past successes & failures, and ability to drive value going forward.
You get access to the actual anonymized transcripts and insights.